Duan Xiaoqiong, Guan Yujuan, Li Yujia, Chen Shan, Li Shilin, Chen Limin
Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Guangzhou No. 8 People's Hospital, Guangzhou, China.
Mediators Inflamm. 2015;2015:508989. doi: 10.1155/2015/508989. Epub 2015 Apr 28.
Calcitriol, the bioactive metabolite of vitamin D, was reported to inhibit HCV production in a synergistic fashion with interferon, a treatment in vitro. Our previous study established that miR-130a inhibits HCV replication by restoring the host innate immune response. We aimed to determine whether there is additive inhibitory effect of calcitriol and miR-130a on HCV replication. Here we showed that calcitriol potentiates the anti-HCV effect of miR-130a in both Con1b replicon and J6/JFH1 culture systems. Intriguingly, this potentiating effect of calcitriol on miR-130a was not through upregulating the expression of cellular miR-130a or through increasing the miR-130a-mediated IFNα/β production. All these findings may contribute to the development of novel anti-HCV therapeutic strategies although the antiviral mechanism needs to be further investigated.
骨化三醇是维生素D的生物活性代谢产物,据报道,它在体外与干扰素协同抑制丙型肝炎病毒(HCV)的产生。我们之前的研究表明,miR-130a通过恢复宿主固有免疫反应来抑制HCV复制。我们旨在确定骨化三醇和miR-130a对HCV复制是否具有相加抑制作用。在此我们表明,在Con1b复制子和J6/JFH1培养系统中,骨化三醇均可增强miR-130a的抗HCV作用。有趣的是,骨化三醇对miR-130a的这种增强作用并非通过上调细胞miR-130a的表达或增加miR-130a介导的IFNα/β产生。尽管抗病毒机制有待进一步研究,但所有这些发现可能有助于开发新的抗HCV治疗策略。